These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Parkinsonism-dementia of Guam: treatment with L-dopa. Schnur JA; Chase TN; Brody JA Neurology; 1971 Dec; 21(12):1236-42. PubMed ID: 4257247 [No Abstract] [Full Text] [Related]
5. Effects of levodopa in Parkinsonian patients with dementia. Sacks OW; Kohl MS; Messeloff CR; Schwartz WF Neurology; 1972 May; 22(5):516-9. PubMed ID: 4673447 [No Abstract] [Full Text] [Related]
6. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. Gumpert J; Sharpe D; Curzon G J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017 [No Abstract] [Full Text] [Related]
7. Effects of L-DOPA treatment on indole metabolism in Parkinson's disease. Brune GG; Pflughaupt KW Experientia; 1971 May; 27(5):516. PubMed ID: 5132580 [No Abstract] [Full Text] [Related]
8. The balance of biogenic amines as condition for normal behaviour. Birkmayer W; Danielczyk W; Neumayer E; Riederer P J Neural Transm; 1972; 33(2):163-78. PubMed ID: 4643007 [No Abstract] [Full Text] [Related]
9. Levodopa and L-tryptophan therapy in Parkinsonism. Coppen A; Metcalfe M; Carroll JD; Morris JG Lancet; 1972 Mar; 1(7752):654-8. PubMed ID: 4125162 [No Abstract] [Full Text] [Related]
10. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor. Rinne UK; Sonninen V; Siirtola T Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542 [No Abstract] [Full Text] [Related]
11. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF. Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388 [No Abstract] [Full Text] [Related]
13. Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease. Bianchine JR; Sunyapridakul L Drugs; 1973; 6(5):364-88. PubMed ID: 4787755 [No Abstract] [Full Text] [Related]
14. Letter: Long term mental changes in levodopa-treated patients. Botez MI; Barbeau A Lancet; 1973 Nov; 302(7836):1028-9. PubMed ID: 4127251 [No Abstract] [Full Text] [Related]
15. [Case reports of some mental disorders in parkinsonian patients treated with L-dopa]. Almici GM; Sbarbaro V Minerva Med; 1974 Feb; 65(8):398-401. PubMed ID: 4820722 [No Abstract] [Full Text] [Related]
16. Conversion of D- and L-tryptophan to brain serotonin and 5-hydroxyindoleacetic acid and to blood serotonin. Yuwiler A J Neurochem; 1973 Apr; 20(4):1099-109. PubMed ID: 4697872 [No Abstract] [Full Text] [Related]
17. Monoamine precursors in the treatment of depression. Carroll BJ Clin Pharmacol Ther; 1971; 12(5):743-61. PubMed ID: 4936139 [No Abstract] [Full Text] [Related]
18. Levodopa and L-tryptophan in parkinsonism. Nistri A Lancet; 1972 Apr; 1(7756):905-6. PubMed ID: 4111864 [No Abstract] [Full Text] [Related]
19. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease. van Woert MH; Bowers MB Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981 [No Abstract] [Full Text] [Related]
20. [Modern treatment of parkinsonism]. Birkmayer W; Neumayer E Z Neurol; 1972; 202(4):257-80. PubMed ID: 4117647 [No Abstract] [Full Text] [Related] [Next] [New Search]